Results 1 - 10 of 20 : 1 2 Next
3 Drugmakers With Multiple Shots on Goal
Well-stocked pipelines could kick these drugmakers into super-high gear.
Flamel Tries to Get It in Gear
The biopharma has irons in the fire, but will they ignite a turnaround?
Will a New Use Help Schering-Plough's Near-Blockbuster Drug?
Delaying relapses probably won't be enough to get its Pegintron approved as a treatment for melanoma.
Exelixis and Glaxo Begin Their Goodbyes
Sometimes, even the best couples break up.
Will InterMune's Hepatitis C Drug Compete?
InterMune announces positive data for one of its drugs.
A Little Bit of Cash for ArQule
ArQule receives a milestone payment from a partner.
Actions speak louder than words.
Lack of Side Effects Doesn't Fatten Arena
Good safety data on its obesity drug fails to plump up the stock price.
The pharmaceutical issues guidance for the coming year.
Credit Crisis Bites Big Pharma
Bristol-Myers Squibb takes a $275 million writedown in its investment portfolio for the quarter.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK